Skip to product information
1 of 1

TWEAK Protein, Human

TWEAK Protein, Human

Catalog Number: UA040544 Brand: UA BIOSCIENCE
Price:
Regular price $300 USD
Regular price Sale price $300 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Synonyms Tumor necrosis factor ligand superfamily member 12, APO3 ligand, TNF-related weak inducer of apoptosis (TWEAK)
Accession O43508
Amino Acid Sequence

Ser94-His249

Expression System HEK293
Molecular Weight

18-20 kDa (Reducing)

Purity >95% by SDS-PAGE, >90% by HPLC.
Endotoxin <0.1EU/μg
Conjugation Unconjugated
Tag No Tag
Physical Appearance Lyophilized powder
Storage Buffer

PBS, pH7.4

Reconstitution

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

Stability & Storage

·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.

Reference

Tumour Biol. 2017 Jun;39(6):1010428317714624.
J Hepatol. 2021 Apr;74(4):860-872.

Background

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), also known as TNFSF12, is a member of the TNF ligand superfamily initially characterized in 1997. TWEAK is synthesized as a type II transmembrane protein and can be proteolytically cleaved by furin into a soluble cytokine. It exerts its biological functions primarily by binding to its receptor, fibroblast growth factor-inducible 14 (Fn14), which contains a TRAF-binding motif that activates downstream signaling cascades including NF-κB, MAPK, PI3K-Akt, and Notch pathways. While Fn14 is the critical signaling receptor, CD163 can also bind soluble TWEAK as a scavenger receptor. The TWEAK/Fn14 axis regulates diverse cellular processes including proliferation, differentiation, migration, angiogenesis, inflammation, and apoptosis, with Fn14 expression being markedly upregulated during tissue injury, inflammation, and regeneration.

Picture

Bioactivity

Measured in a cell proliferation assay using HT-29 human colon adenocarcinoma cells, the IC50 for this effect is 1.5-8.8 ng/ml.

SDS-PAGE

2μg (R: reducing condition, N: non-reducing condition).

RP-HPLC

>90% as determined by RP-HPLC.